AU2002364381A1 - Hypertonia treatment during the acute phase of a cerebrovascular accident - Google Patents
Hypertonia treatment during the acute phase of a cerebrovascular accident Download PDFInfo
- Publication number
- AU2002364381A1 AU2002364381A1 AU2002364381A AU2002364381A AU2002364381A1 AU 2002364381 A1 AU2002364381 A1 AU 2002364381A1 AU 2002364381 A AU2002364381 A AU 2002364381A AU 2002364381 A AU2002364381 A AU 2002364381A AU 2002364381 A1 AU2002364381 A1 AU 2002364381A1
- Authority
- AU
- Australia
- Prior art keywords
- use according
- cerebrovascular accident
- treatment
- cerebrovascular
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006011 Stroke Diseases 0.000 title claims description 43
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims description 20
- 208000026106 cerebrovascular disease Diseases 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title claims description 16
- 230000001154 acute effect Effects 0.000 title description 9
- 206010020852 Hypertonia Diseases 0.000 title description 3
- 230000036772 blood pressure Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 10
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims description 8
- 230000036454 renin-angiotensin system Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 229960004349 candesartan cilexetil Drugs 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 229960000932 candesartan Drugs 0.000 claims description 3
- 230000003205 diastolic effect Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical group C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 2
- 229950000973 omapatrilat Drugs 0.000 claims description 2
- 229940097258 other antihypertensives in atc Drugs 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000009862 primary prevention Effects 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- YGULWPYYGQCFMP-CEAXSRTFSA-N Metoprolol tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 YGULWPYYGQCFMP-CEAXSRTFSA-N 0.000 description 1
- 206010049415 Renin-angiotensin system inhibition Diseases 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- -1 quinalapril Chemical compound 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10157474.6 | 2001-11-23 | ||
| DE10157474 | 2001-11-23 | ||
| DE10158030.4 | 2001-11-27 | ||
| DE10158030 | 2001-11-27 | ||
| PCT/EP2002/013238 WO2003043615A2 (fr) | 2001-11-23 | 2002-11-25 | Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002364381A1 true AU2002364381A1 (en) | 2003-06-10 |
Family
ID=26010631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002364381A Abandoned AU2002364381A1 (en) | 2001-11-23 | 2002-11-25 | Hypertonia treatment during the acute phase of a cerebrovascular accident |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050009893A1 (fr) |
| EP (1) | EP1450793A2 (fr) |
| JP (1) | JP2005511631A (fr) |
| AU (1) | AU2002364381A1 (fr) |
| BR (1) | BR0214383A (fr) |
| CA (1) | CA2467095A1 (fr) |
| MX (1) | MXPA04004844A (fr) |
| PL (1) | PL370270A1 (fr) |
| WO (1) | WO2003043615A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| PL353199A1 (en) * | 1999-08-30 | 2003-11-03 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| WO2012024657A1 (fr) | 2010-08-20 | 2012-02-23 | IntegenX, Inc. | Dispositifs microfluidiques pourvus de soupapes à diaphragme mécaniquement scellées |
| US8633158B1 (en) | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| US9333233B2 (en) * | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| CA2048699A1 (fr) * | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Methode de prevention ou de traitement des maladies cerebro-vasculaires faisant appel au ceronapril |
| US20010018448A1 (en) * | 1990-12-14 | 2001-08-30 | Smithkline Beecham P.L.C. | Medicament |
| GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| DK0889880T3 (da) * | 1996-03-29 | 2003-09-01 | Smithkline Beecham Corp | Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering |
| CA2677910C (fr) * | 1997-10-17 | 2011-03-15 | Ark Therapeutics Limited | Utilisation d'inhibiteurs du systeme renine-angiotensine pour le traitement de maladies cardiovasculaires |
| US6248729B1 (en) * | 1998-06-17 | 2001-06-19 | Bristol-Myers Squibb Co. | Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
| FR2783422A1 (fr) * | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
| DE60037192T2 (de) * | 1999-07-21 | 2008-05-15 | Takeda Pharmaceutical Co. Ltd. | Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens |
| PL353199A1 (en) * | 1999-08-30 | 2003-11-03 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| AU2001242184A1 (en) * | 2000-03-28 | 2001-10-08 | Queen:S University At Kingston | Methods for effecting neuroprotection using a potassium channel modulator |
| CA2405793A1 (fr) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combinaison de composes organiques |
| BR0017386A (pt) * | 2000-12-18 | 2004-01-13 | Novartis Ag | Combinação terapêutica de amlodipina e benazepril |
| DE10115668A1 (de) * | 2001-03-29 | 2002-10-10 | Max Delbrueck Centrum | Mittel zur Behandlung des Schlaganfalls |
-
2002
- 2002-11-25 JP JP2003545296A patent/JP2005511631A/ja not_active Withdrawn
- 2002-11-25 BR BR0214383-6A patent/BR0214383A/pt not_active IP Right Cessation
- 2002-11-25 WO PCT/EP2002/013238 patent/WO2003043615A2/fr not_active Application Discontinuation
- 2002-11-25 PL PL02370270A patent/PL370270A1/xx not_active Application Discontinuation
- 2002-11-25 EP EP02799727A patent/EP1450793A2/fr not_active Withdrawn
- 2002-11-25 MX MXPA04004844A patent/MXPA04004844A/es unknown
- 2002-11-25 CA CA002467095A patent/CA2467095A1/fr not_active Abandoned
- 2002-11-25 AU AU2002364381A patent/AU2002364381A1/en not_active Abandoned
-
2004
- 2004-05-24 US US10/851,660 patent/US20050009893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL370270A1 (en) | 2005-05-16 |
| EP1450793A2 (fr) | 2004-09-01 |
| BR0214383A (pt) | 2004-11-03 |
| JP2005511631A (ja) | 2005-04-28 |
| US20050009893A1 (en) | 2005-01-13 |
| WO2003043615A2 (fr) | 2003-05-30 |
| MXPA04004844A (es) | 2004-07-30 |
| CA2467095A1 (fr) | 2003-05-30 |
| WO2003043615A3 (fr) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114344293B (zh) | 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂 | |
| Balakumar et al. | Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated | |
| GB2270074A (en) | Angiotensin II antagonist | |
| AU2002364381A1 (en) | Hypertonia treatment during the acute phase of a cerebrovascular accident | |
| Camargo et al. | DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet | |
| AU2004216133B2 (en) | Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases | |
| WO1993020816A1 (fr) | Antagonistes d'angiotensine ii utilises pour traiter les troubles associes a une vitesse de conduction neuronale insuffisante, notamment la neuropathie diabetique | |
| TWI354553B (en) | Drug for glomerular diseases | |
| KR102259938B1 (ko) | 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체 | |
| ZA200106022B (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction. | |
| KR20180123021A (ko) | 신질환의 치료를 위한 의약 | |
| JP2008133229A (ja) | 医薬組成物 | |
| CN101522194A (zh) | 肾功能障碍预防/治疗剂 | |
| Sood et al. | Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension | |
| EP1731169A1 (fr) | Remèdes pour l' hypertrophie de la prostate | |
| EP3852757A1 (fr) | Inhibiteurs de ch24h pour une utilisation contre la douleur | |
| CN110292637A (zh) | 一种预防、治疗高血压的药物组合物 | |
| Bell et al. | Low-dose captopril in the treatment of severe refractory hypertension associated with renal failure | |
| CN1753669A (zh) | 中风急性期的高血压治疗 | |
| Lisy et al. | O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP | |
| Rossi et al. | O-39: Comparative effects of the dual ACE and vasopeptidase inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease (CVD) in endogenous angiotensin II-dependent hypertension | |
| CA2498049A1 (fr) | Antagonistes de recepteur at<sb>1</sb> permettant de prevenir des accidents vasculaires cerebraux secondaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period | ||
| TH | Corrigenda |
Free format text: IN VOL 20, NO 15, PAGE(S) 1437 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTSCEASED OR EXPIRED - 2002 DELETE ALL REFERENCE TO 2002364381 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |